# Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

> **NCT01310803** · PHASE3 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Carcinoma in Situ
- Transitional Cell Carcinoma
- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** VALSTAR - Maintenance Therapy
- **OTHER:** No Maintenance treatment ( Standard of Care)

## Key facts

- **NCT ID:** NCT01310803
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310803, "Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01310803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*